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Abstract  
 
Microparticles are a distinctive group of small vesicles, without nucleus, which are involved 
as significant modulators in several physiological and pathophysiological mechanisms.  
 
Plasma microparticles from various cellular lines have been subject of research. Data suggest 
that they are key players in development and manifestation of cardiovascular diseases and 
their presence, in high levels, is associated with chronic inflammation, endothelial damage 
and thrombosis. The strong correlation of microparticle levels with several outcomes in 
cardiovascular diseases has led to their utilisation as biomarkers. Despite the limited clinical 
application at present, their significance emerges, mainly because their detection and 
enumeration methods are improving.  
 
This review article summarises the evidence derived from research, related with the genesis 
and the function of microparticles in the presence of various cardiovascular risk factors and 
conditions. The current data provide a substrate for several theories of how microparticles 
influence various cellular mechanisms by transferring biological information.  
 
(148 words) 
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Key messages 
 Formation of microparticles, after physiological or pathophysiological cellular 
stimulation, may activate mechanisms related to coagulation, inflammation and 
angiogenesis, mainly by transferring biological information from the paternal cells. 
  Data from research suggest that risk factors for cardiovascular diseases are associated 
with high levels of microparticles from different cellular lines. 
 Manifestation and activity of cardiovascular diseases partly regulated by the presence 
and levels of microparticles. 
 Utilisation of microparticles as biomarkers emerges and there is evidence that their 
levels might also have prognostic value for several cardiovascular pathological 
conditions.   
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1.Introduction 
 
Both eukaryotic and prokaryotic cells, under the influence of several external or internal 
factors, can produce small vesicles. These vesicles are enclosed in a biphospholipid layer and 
contain part of the paternal cytosol(1). Part of this heterogeneous population of cell-derived 
vesicles are the microparticles which serve as a disseminated storage pool of active biological 
molecules(2). For long time after their discovery, microparticles were considered as cell 
debris, result of biological processes without any significant meaning. However, 
technological advantages of their detection and characterisation stimulated research for 
investigation of their roles in various clinical situations(3).  
 
The current evidence suggests that microparticles formation from different types of cells, in 
normal circumstances, is not just a passive process following apoptosis, necrosis or cellular 
dysfunction but is a balanced mechanism that promotes communication between various 
cellular types. Microparticles influence vital physiological functions such as inflammation, 
coagulation, apoptosis and cell differentiation and may trigger pathophysiological 
mechanisms which contribute to the genesis of atherosclerosis and thrombosis, the 
cornerstones for the development of cardiovascular disorders(4). Apart from the current role 
as reflectors/biomarkers of certain cardiovascular and other diseases, microparticles have 
been proposed as potential targets in order to regulate various conditions with auto-immune 
or thrombotic causality(5). 
 
This review article summarises the evidence derived from research, related with the genesis 
and the function of microparticles in the presence of various cardiovascular risk factors and 
conditions. 
 
2. Definition and Nomenclature 
 
Knowledge on extracellular vesicles have significantly expanded over the last 2 decades.  
Even at the last meeting of International Society of Extracellular Vesicles in 2018, there was 
no definitive consensus about the definition of microparticles(6).  
 
The broad term to describe particles released from cells by natural process such that their 
cytosol is enclosed by a lipid bilayer and lacking synthetic capacity, is “extracellular 
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vesicles”. The term ‘microparticles’ has been used for a variety of extracellular vesicles in the 
past. The distinction of exosomes and ectosomes (Figure 1) is important in order to approach 
the nature of microparticles. Exosomes are formed after an inward bledding of the plasma 
membrane and stored into a bigger intracellular vesicle, the multivesicular body. Later, 
exosomes can be released in the extracellular environment by exocytosis. On the contrary, 
ectosomes are vesicles which directly released from the paternal cell by outwards 
rearrangement of the cellular membrane(7). Of note, there is a significant overlap regarding 
size (diameter), membrane protein composition and cellular origin of the extracellular 
vesicles which at present makes difficult their categorisation(8). Even their characterisation 
as ectosomes or exosomes is generally not advisable unless particle biogenesis is documented 
by a live imaging technique(6).  
 
Other types of extracellular vesicles are the apoptotic bodies which have usually a diameter 
between 1-5µm. Formation of apoptotic bodies is exclusively linked to the latest stages of 
apoptosis where there is cellular shrinkage and nuclear fragmentation. Nuclear material, cell 
organelles and a permeable membrane are distinguishable characteristics of apoptotic 
bodies(9). In general, ectosomes are larger than exosomes (30-100nm) and smaller than 
apoptotic bodies(Figure 1). Additionally,  the content may be different. For example, 
exosomes contain some membrane specific markers which are related with their formation 
process, such as lysosomal-associated membrane protein 1 and the membrane protein CD63. 
For microparticles, externalisation of the negatively charged phospholipid phosphatidylserine 
is the rule but for exosomes it is a rare structural condition. Also exosomes might contain 
cytosolic RNA but not like microparticles nuclear material(10). The above “rules” have 
exceptions to the degree that specific identification criteria based on size and/or markers 
seems to be causing more confusion than consensus(11). 
 
In this review, we have included research articles related with extracellular vesicles which 
their diameter is between 100nm-1µm and they have at least one marker to describe their 
membrane biochemical composition. Furthermore, the cell(s) of origin are usually known to 
be related either with the biomarker or with the experimental process and the analysis 
method. In the vast majority of the literature these vesicles are called “microparticles” and 
thus, we kept that term.   
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3. Biology  
 
3.1 Inducers and mechanisms of formation 
 
Potentially, any cell of an eukaryotic organism can produce microparticles(12). In the blood, 
the most common(70-90%) of the circulating microparticles are platelet derived 
microparticles. The rest of the blood containing microparticles are from endothelial, 
granulocyte, erythrocyte and smooth-muscle cells(13). Microparticles from epithelial, tumour 
cells, fibroblasts and other cellular origin have been also isolated(14,15).  
 
Apart from the formation of the microparticles under normal circumstances, which is mainly 
linked with growth, differentiation and apoptosis(16), there are other non-physiological 
conditions that promote microparticle production. These conditions include hypoxia(17), 
shear stress(18), inflammation(19) and a variety of prothrombotic or proapoptotic 
factors(20)(Table 1). Usually, the first  result after exposure of the cell to these factors, is an 
increase of Ca
+2 
influx(21)(Figure 2). High concentration of the intracellular Ca
+2
 induces 
molecular processes resulting in the release of the microparticles in the extracellular 
media(21). 
 
The general assumption is that loss of the phospholipid asymmetrical set up of the plasma 
membrane, which is present during cellular relaxation, leads to the production of the 
microparticles(22). Externalisation of phosphatidylserine, a negative charged phospholipid, 
primarily located on the inner surface of the plasma membrane of the non-activated cell, 
results in the membrane asymmetry(23). Several phospholipid transporters regulate the 
inwards (flip) or outwards (flop) translocation of the plasma membrane lipids. An ATP-
dependent “floppase” is responsible for the outwards translocation of the phosphatidylserine 
with simultaneous inhibition of flippase(s)(24). Non-specific, bidirectional lipid transporters, 
the “scramblases” (25) along with the formation of transient membrane pores constitute 
another pathway for the membrane remodelling(26).   
 
The intracellular influx of Ca
+2 
is also involved in the shaping of the plasma membrane 
protrusions which results in the formation of microparticles(22). This process begins with 
degradation and reconfiguration of the cytoskeleton proteins(27). The proteolysis of specific 
part of the cytoskeleton network, by calpain activation, causes separation of the membrane 
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protrusion from the parental cell as independent vesicle into the extracellular media(28). 
Another group of proteases, the capsases, is also associated with cytoskeleton ingredient lysis 
like talin, filamin, and gelsolin(29). Capsases are involved in the actin-myosin cytoskeletal 
network reorganisation by interacting with various Rho-kinases isoforms(30,31). Rho-kinases 
mediated microparticle shedding, with possible cellular nucleic acid redistribution, appears to 
be involved in apoptotic processes(32).  
 
Phosphatidylserine exposure is commonly involved in microparticle formation from activated 
or apoptotic cells(33). However, there are less controlled situations where stress or injury 
induce cellular necrosis and loss of membrane integrity with production of 
microparticles(34). Also, there are populations of microparticles that are phosphatidylserine- 
(i.e., they do not bind Annexin-V), suggesting alternative formation processes(35). Further 
evidence of other ion channel involvement in the microparticle formation cascade, apart from 
Ca
+2
, support the presence of unknown mechanisms associated with plasma membrane 
shedding(36).  
 
(Table 1) 
 
 
3.2 Structure and content 
 
Microparticles contain a wide variety of biological molecules as part of their phospholipid 
membrane or within the cytosol that they enclose (Figure 3). These molecules are proteins 
(signal proteins, receptors, effector proteins), lipids and nucleic acids (38–40). Various 
techniques have been tried in order to characterize the components of the microparticles 
(41,42). Irrespective of the origin of microparticles, the plasma membrane is negatively 
charged due to translocation of phospholipids such as phosphatidylserine and 
phosphatidylcholine from internal to external surface(43,44). Other phospholipids of the 
membrane include lysophosphatidylcholine, sphingomyelin, lysophosphatidylethanolamine, 
phosphatidylethanolamine, lysophosphatidylserine, and phosphatidylinositol(45). It appears 
that the bi-lipid layer of the microparticles affects the attached protein activities and the 
general properties of the vesicles(46). 
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The origin of the microparticles influences their composition. For example, platelet derived 
microparticles are enrich in various membrane proteins that are important in the coagulation 
process such us GPIb, GPII-IIIb, P-selectin, intergrins(47–49). Similarly, microparticles from 
endothelial cells carry characteristic endothelial proteins (vascular endothelium cadherin, E-
selectin)(50) and leucocyte derived microparticles are enriched in metalloproteinases and 
other proteolytic enzymes(51) involved in inflammation process. Antigenic clusters of 
differentiation (CD31, CD105, etc) which derive directly from the parental cell, are present in 
the plasma membrane of the microparticles(52) (Table 2).  
 
The stimuli that triggers the formation of the microparticles regulates the ratio and the 
composition of the expressed membrane proteins. For example, monocytes have been 
stimulated by various substances in vitro (lipopolysaccharide, soluble P-selectin chimera, 
phosphate-buffered saline) and the produced microparticles expressing different membrane 
proteins.  Similar findings were reported for microparticles derived from other cellular lines 
such as T cells(53), endothelial cells(52) and leucocytes(54). However, all microparticles 
shared some common molecules(55). 
 
The nucleic acids contained into the microparticles are usually result of apoptotic 
process(56). Different types of RNA (ribosomal, micro and messenger) and DNA are 
enclosed into membrane vesicles which are protected from nuclease exposure and might be 
activated into the target cells. RNA packaging is influenced by the variation of the stimuli 
that trigger microparticle formation(57). This selective translocation of nucleic acids 
contributes to intercellular communication(58,59). 
 
(Table 2) 
 
4. Functions related with cardiovascular physiology 
 
4.1 Transfer of Biological information 
 
Several biological functions of microparticles can be summarised with the title “factors of 
intercellular communication and information exchange”. In principle, there are 2 ways 
microparticles may contribute to intercellular signalling. The first is mediated by activation of 
receptors on the plasma membrane of the target cell by presentation of molecules which 
Ac
ce
pt
ed
 M
nu
sc
rip
t
result in alteration of the cellular function. The second way of interaction is by direct transfer 
to the target cell bioactive components such as proteins, lipids and nucleic acids (Table 3). 
The target cell can utilise these molecules by affecting its biological function by activation of 
certain pathways or by phenotypic modification(48,72,73). Phenotypic modification is 
achieved usually by transferring membrane receptors to the recipient cell. These receptors 
interfere with stimuli that before transfer did not influence cellular activity at all or not by the 
same way(74).  
 
Proteins can also be carriers of biological signal. Apart from membrane proteins, 
microparticles might have proteins in their cytosol in various forms. After incorporation of 
the microparticles into the target cell by phagocytosis, the proteomic load can be in an 
activated form or can be cleaved and activated by proteolytic enzymes into the target 
cell(75,76).  
 
Reverse transcription polymerase chain reaction and microarray analysis demonstrated that 
microparticles carry a specific subset of messenger RNA or microRNA from the origin 
cell(76). By this manner, microparticles transfer to the target cell transcriptional information, 
analogous to the stimulating factor. The recipient cell will promote several processes, such as 
differentiation, proliferation and apoptosis by expressing different gene(77,78).  
 
Lipids are not only components of the plasma membrane of the microparticles but actively 
determine the role of the ectosomes and their interaction with other cells(79). This function is 
mediated by the surface provided by microparticle membrane and from bioactive lipids such 
as arachidonic acid, cyclooxygenase 2 and prostacyclin(80,81). 
 
 
(Table 3) 
 
 
4.2 Coagulation 
 
The involvement of microparticles in the coagulation process was apparent from the time of 
their discovery(102). The strongest procoagulant activity is mainly related to the negatively 
charged, external surface of their plasma membrane due to the presence of 
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phosphatidylserine. The phosphatidylserine electrostatically attracts the positively charged 
segment of clotting proteins such as factors VII, IX and X, and prothrombin. The presence of 
γ-carboxyglutamic acid (GLA) domains creates the cationic features of these clotting 
factors(103)(Figure 4). 
   
Additionally, tissue factor as plasma membrane protein of the microparticles appears to play 
key role in the coagulation process. Tissue factor is an integral protein of the coagulation 
cascade and acts as a receptor of the FVII/VIIa complex, which activates both factors IX and 
X to initiate thrombin formation. Tissue factor positive microparticles may derive from 
monocytes, neutrophils, endothelial cells and platelets as response to various pathological 
conditions(104). P-selectin, a cell adhesion receptor, interacts with tissue factor positive 
microparticles, through P-selectin glycoprotein ligand 1 (PSGL-1) on monocytes and causes 
further tissue factor positive microparticles generation which carry PSGL-1. These 
microparticles bind to activated platelets on the site of vascular injury and contribute further 
to thrombus expansion(105).  
 
Finally, another possible mechanism of microparticles prothrombotic actions is inhibition of 
the fibrinolytic process. Expression of proteins on the plasma membrane of microparticles 
like plasminogen activator inhibitor-1 and protein S, leads to amplification of thrombogenesis 
by suppression of fibrinolysis(106,107). 
 
4.3 Inflammation and immune regulation 
 
Part of intercellular communication features of microparticles has been related with the 
immune regulation. Immune and non-immune cells may produce microparticles which carry 
antigens.  In this context, microparticles can influence immune responses to foreign(108) or 
self-antigens(109). All immune cell types under certain stimuli can generate microparticles 
but the most effective, with regard to the regulation of immune response, are the 
“professional” antigen-presenting cells, such as dendritic cells, macrophages, and B 
cells(110). This is achieved by binding the antigen to the cell surface or by 
phagocytosis(111,112).  
 
Microparticles have pro-inflammatory effects mainly by inducing the production of cytokines 
and chemokines and by the activation of inflammatory cells(37)(Table 4). This recruitment of 
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Administration of endothelial microparticles to rats is associated with release of pro-
inflammatory cytokines IL-1β and TNF-α, acute lung injury and histological damage as 
evidence from the neutrophil infiltration into the perivascular space(114).  
 
In vitro studies reported release of cytokines IL-6 and monocyte chemotactic protein from 
endothelial cells after stimulation by neutrophil microparticles(115). Furthermore, pro-
inflammatory cytokine secretion, such as IL-8, TNF-a and IL-1β, have been described from 
other cellular cultures after exposure to microparticles(43,116).  
 
In addition to chemotactic factors, microparticles are involved in the production of specific 
cellular membrane proteins which promote adhesion of inflammatory cells to endothelium. 
Examples are the intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-
selectin(95,117). Bioactive lipids produced by platelet derived microparticles, like 
thromboxane A2 and cyclooxygenase, may act as mediators of inflammation. The target 
tissue is usually the endothelium(79). 
 
Cases have been described where microparticles from polymorphonuclear leukocytes 
antagonise parallel pro-inflammatory stimuli by releasing cytokines like transforming growth 
factor beta 1. Polymorphonuclear derived microparticles also contain annexin 1, a protein 
with anti-inflammatory properties. Annexin-1 and transforming growth factor beta 1 inhibit 
macrophages. This action usually occurs during the early stages of the inflammatory 
process(118,119). Microparticles from monocytes were found to induce macrophages and 
monocytes expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) 
protein with anti-inflammatory action. In the same study, monocyte microparticles promoted 
inflammatory [reactive oxygen species (ROS), cytokines] or anti-inflammatory (PPAR-γ) 
molecules in dose dependant manner(120).  Another mechanism which associated with 
polymorphonuclear derived microparticles mediated inflammatory process is activation of 
complement. Purified complement proteins like C1q from serum were found to be carried by 
polymorphonuclear derived microparticles(51).  
 
 
 (Table 4) 
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4.4 Angiogenesis 
 
The platelet derived microparticles were the first group of microvesicles demonstrated 
angiogenetic properties in vitro. Platelets are known carriers of neovascularisation factors.  
Bioactive lipids from platelet derived microparticles (Table 5) are the main inducers of 
proliferation and tube formation in human umbilical vein endothelial cells(90,121). 
Experiments in rat models reported angiogenesis in ischaemic myocardium after injection of 
platelet derived microparticles. The process was facilitated by vascular endothelial growth 
factor, basic fibroblast growth factor and inhibition of platelet factor-4(91). Also, tissue factor 
positive  microparticles can induce endothelial cell proliferation through a beta 1-integrin and 
extracellular signal regulated kinase activation(122). 
 
Another microparticle related neovascularisation mechanism is possibly associated with the 
morphogen Sonic Hedgehog pathway. T-cell derived microparticles, harbouring the Sonic 
Hedgehog antigen, promote in vitro and in vivo formation of new vascular network by 
regulating the nitric oxide pathway and stimulate genes coding expression of adhesion 
molecules and proangiogenic factors(123,124). 
 
Endothelial derived microparticles have also angiogenetic properties. Plasmin formation on 
the surface of the endothelial derived microparticles might activate proteolytic pathways and 
generation of factors which promote tube formation from endothelial cells(125). In addition, 
matrix metalloproteinases carried by endothelial derived microparticles contribute to matrix-
degrading proteolytic activity necessary for the angiogenetic events(126). Neovascularization 
programming by endothelial derived microparticles appears to be conducted in relation with 
direct transfer of mRNA to target endothelial cells which codifies the formation of capillary-
like structures(38). In vivo demonstration of the angiogenetic features of microparticles was 
reported by Leroyer et al(127). Microparticles derived from ischaemic muscle injected into 
ischemic legs in a rat model resulted in enhanced neovascularization. 
 
Adipose cell derived microparticles from rats was also found to be carriers of angiogenetic 
molecules, such as leptin, fibroblast growth factor alpha (FGFa) and TNFa and in 
collaboration with tissue matrix metalloprotease (MMP)-2 and MMP-9 may promote 
neovascularization(128). 
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A combined signal transmission from microparticles that regulates the functions of 
angiogenesis, apoptosis, differentiation and migration might contribute to tissue regeneration 
and remodelling(129). After permanent middle cerebral artery occlusion in rats, 
administration of platelet derived microparticles increased neurogenetic and angiogenetic 
activity, followed by behavioural improvement but no changes in infracted volumes(130).  
 
The role of microparticles in angiogenesis is not always promotive but may be inhibitory. 
There are reports about prevention of neovascularization by microparticles. For example, 
human umbilical vein endothelial cells vascular network proliferation was inhibited by the 
presence of endothelial derived microparticles(131). Similarly, lymphocyte-derived 
microparticles were found to cause overexpression of the CD36 anti-angiogenic receptor 
while significantly downregulated protein levels related with angiogenesis(132). The 
generation of reactive oxygen species such as hyperoxide is likely to be involved in the 
inhibitory process. The balance between inhibition and promotion of neovascularization, for 
different types of microparticles, appears to be affected by their concentration along with 
other potential unknown factors (126,132,133).  
 
(Table 5) 
 
 
4.5 Regulation of vascular tone 
 
Several studies have established a link between endothelial activity, expressed by 
modification of vascular tone and microparticles. Microparticles may affect the regulation of 
nitric oxide synthetase resulting in impaired production of nitric oxide in vivo(108,134). 
Endothelial derived microparticle may also impair vasorelaxation. This was demonstrated in 
patients with end stage renal failure and type 2 diabetes, where different sonographic indices 
of arterial function have been assessed(61,135). Furthermore, endothelial relaxation was 
impaired in aortic rings after exposure to endothelial derived microparticles from patients 
with recent myocardial infarction, in contrast with endothelial derived microparticles from 
non-ischaemic patients(136).  
 
Lymphocyte derived microparticles also affect the nitric oxide synthetase activity(137,138). 
The mechanism driven the synthetase downregulation is related with the phosphorylation of 
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the extracellular signal–regulated kinase 1/2 via phosphatidylinositol-3-kinase and nuclear 
factor -light-chain-enhancer of activated B cell pathways(137). Additionally, lymphocyte 
derived microparticles may induce endothelial overexpression of the integral membrane 
protein caveolin-1 which inhibits the nitric oxide synthetase(138).  
 
Endothelial and platelet derived microparticles are carriers of endothelial nitric oxide 
synthase and in patients with cardiovascular risk factors the isolated microparticles found to 
have significant less levels of the synthase compared with healthy subjects(139). Platelet 
derived microparticles can also influence the vascular tone as they are involved in the 
production of vasoactive molecules such as prostacyclin (vasodilator)(80) or thromboxane 
(vasoconstrictor) (140). In experimental models, microparticles can modify cyclo-oxygenase 
metabolites levels through the Fas antigen and its natural ligand FasL pathway(141).   
 
4.6 Apoptosis 
 
Microparticles production can be the result from an apoptotic process along with the 
formation of apoptotic bodies. Additionally, microparticles can also induce programmed 
cellular death of remote cells(142,143). Anti-apoptotic stimulation showed a reduction in the 
cell “blebbing” and microparticle formation in Human tonsil germinal center B cells in vitro. 
B cell blebs appear to have chemo-attractive properties to macrophages which carry out the 
apoptotic cell removal(144). Endothelial derived microparticles can initiate apoptosis in 
angiogenic cells. The rich in arachidonic acid microparticles are phagocytosed by the 
angiogenic cells and signalise apoptosis. This action, as other functional roles of the 
microparticles, is concentration dependant(145). Apoptosis mediated by the lipid synthesis of 
the microparticle is also possible, even without involvement of phagocytosis. PtdIns(3,5)BP 
is a specific inhibitor of the acid sphingomyelinase which can inhibit the apoptosis pathway 
via upregulation of the capsase-8. Inhibition of the extracellular signal regulated kinase 1 
prevents the apoptosis of macrophages in vitro. Extracellular signal regulated kinase 1 as 
microparticle membrane protein activate target cell membrane phospholipases and 
contributes to formation of arachidonic acid from phospholipids(146). Capsase-3 protein is 
also involved in apoptosis(147) and has been identified as membrane protein in platelet 
derived microparticles and endothelial derived microparticles(148,149).  
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The signal for programmed cellular death to remote cells can be transmitted by microparticles 
through the Fas antigen and its natural ligand FasL.  This mechanism was demonstrated in 
human tumour cells in vitro(150). Additionally, tumour derived microparticles contain matrix 
metalloproteinases responsible for matrix degradation but also adhesion molecules and 
receptors like the CX3CL1/fractalkine system which regulates migration and apoptosis(151). 
 
4.7 Oxidative stress 
 
Oxidative stress is caused when there is an imbalance between production of reactive oxygen 
species and the antioxidant defence mechanisms(152). Controlled production of reactive 
oxygen species is important as contributes to cell growth, adhesion, differentiation, and 
apoptosis(153). Brodsky et al(134) reported an active role of endothelial derived 
microparticles in the formation of superoxide. Also, the p22(phox) subunit of NADPH 
oxidase has been detected in endothelial derived microparticles. Also, microparticles from 
other cellular origin, such as lymphocytes and monocytes, may lead to the production of 
reactive oxygen species(132,154). Monocyte derived microparticles can induce nitrosative 
stress in endothelial cells in vitro. This occurs by increasing the nitration of several proteins 
in endothelial cells after regulating calveolin-1 expression or activation of 
phosphatidylinositide-3 kinase and other extracellular signal–regulated kinases(155).  
 
 
5. Microparticles and cardiovascular risk factors 
 
5.1 Essential Hypertension 
 
Mechanisms, such as excessive amounts of reactive oxygen species and oxidative stress, 
which are linked with microparticles, have been described to be involved in the pathogenesis 
of endothelial dysfunction due to hypertension(156,157).  
 
The Renin-angiotensin system in known to have a fundamental role in the regulation of 
arterial hypertension(158). Angiotensin II, a potent vasoconstrictive hormone can induce the 
formation of microparticles from monocytes in vitro. The derived microparticles expressed 
tissue factor on their membrane and demonstrated procoagulant activity(159). Procoagulant 
features of microparticles reported by Preston et al(160) in patients with severe hypertension. 
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The hypertensive cohort had increased levels of platelet and endothelial derived 
microparticles with  strong positive correlation between two types circulating microparticles 
(CD31+ endothelial derived microparticles and CD62P + platelet derived microparticles) and 
absolute levels of systolic and diastolic blood pressure. Tissue factor expression on 
endothelial derived microparticle and platelet factor 3 on platelet derived microparticles 
might explain the procoagulant features of microparticles and thrombogenity of hypertension.  
  
High levels of circulating endothelial derived microparticles with synchronous reduction of 
endothelial progenitor cells (EPC) as expressed by increased ratio of endothelial derived 
microparticles/EPC were detected in hypertensive patients with reduced glomerular filtration 
rate and microalbuminuria. The endothelial progenitor cells are considered to promote 
endothelial integrity and vascular repair. On the other hand, the CD31/annexin V+ apoptotic 
microparticles were related with atherosclerotic disease and further deterioration of the renal 
function(161,162).   
 
5.2 Diabetes mellitus 
 
Endothelial derived microparticles(CD62E+) are higher in a pre-diabetic cohort along with 
elevated biomarkers of endothelial dysfunction(163)(Table 6), suggesting an involvement of 
microvesicles in the pathogenesis of the disease. In patients with established diabetes, the 
absolute number of microparticles was also found to be elevated.  Kurtzman et al(164) 
reported increased number of several microparticle phenotypes in diabetics compared with 
healthy controls(164). Similar findings were demonstrated by a metanalysis of 48 studies 
involving 2,460 patients with Type 2 diabetes(165).  
 
Different types of microparticles, such as endothelial, platelet, erythrocyte and monocyte 
derived microparticles have also been found to be elevated in diabetic populations(61,166–
168). Monocyte, endothelial and platelet derived microparticles are significantly higher in 
diabetic patients with related vascular complications such as nephropathy, retinopathy or 
neuropathy compared with diabetic patients without complications(63,167,169,170).  
 
Patients with type 1 diabetes mellitus have not only higher but also different types of 
circulating microparticles compared with patients with type 2 diabetes mellitus and healthy 
people(65). Platelet, endothelial and apoptotic cell (annexin V+) derived  microparticles were 
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significantly elevated in type 1 diabetes. The different microparticle phenotypes between the 
two conditions reflect differences in their functional and particularly their procoagulant 
properties. For type 2 diabetes patients, these microparticles have limited procoagulant action 
but for type 1 diabetes their prothrombotic properties were positively correlated with the 
glycaemic control [HbA1c](65). The relation between glycaemic control and microparticles 
have been demonstrated in a study of overweight subjects with type 2 diabetes. The levels of 
the circulating microparticles have been reduced  after bariatric surgery with synchronous 
normalization of glycaemic control (69). 
 
The pathophysiology of hypercoagulopathy in diabetes has been linked with the presence of 
microparticles(65,171,172). Abnormal production of reactive oxygen species mediated by 
microparticles along with inappropriate protein expression on the microparticle membrane 
which relate to coagulation and immune pathways have been demonstrated in vitro(172). 
Tissue factor antigens on the membrane of circulating microparticles in patients with type 2 
diabetes was reported by Cimmino et al(171) and is likely to be involved in the 
prothrombotic activity along with other athero-imflammatory processes observed in diabetic 
populations. Microparticle coagulability (expressed by the density of membrane tissue factor 
and membrane tissue factor pathway inhibitor ratio) was found to be high in diabetic patients 
with severe foot ulcers and manifestations of coronary artery disease(173). Similar findings 
regarding hypercoagulability of plasma microparticles in diabetic patients reported by 
Tripodi et al(174) as measured and correlated by conventional coagulation tests such us 
antithrombin and  protein C activity and levels of factors II and VIII.  
 
Diabetic vascular complications are associated with vascular inflammation and endothelial 
dysfunction(175). Endocytosis of platelet derived microparticles from endothelial cells in 
vitro induced expression of von Willebrand factor on the plasma membrane of the endothelial 
cells, which promoted adhesion of platelets and excessive production of reactive oxygen 
species leading to inflammation(67). Microparticles mediated reactive oxygen species 
production in diabetics is involved in downregulation of NO activity affecting the vascular 
tone and contribute to leukocytes chemotaxis to endothelium by expression of surface 
antigens(176,177). In clinical studies, type 2 diabetes, is associated with high levels of 
endothelial/apoptotic cell derived microparticles and asymptomatic coronary atherosclerotic 
disease(178). 
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Microparticles have been demonstrated to be involved in impaired neovascularization process 
in diabetic populations. Incubation of human umbilical vein endothelial cells with 
extracellular microvesicles from patients with diabetic foot or diabetic retinopathy induced 
the formation of tube networks, suggesting an important role of the vesicles in the process of 
angiogenesis(173). Tissue factor positive microparticles in well controlled diabetic patients 
are not always involved in coagulation process and potentially have a role in signal 
transmission, including angiogenesis(70,179). MiR-126, a type of RNA, which is contained 
in microparticles was reported to play important role in endothelial integrity and 
angiogenesis(180). Reduced expression of miR-126 in endothelial derived microparticles 
from diabetic patients might contribute to endothelial injury,  abnormal vascular remodelling 
and impaired angiogenesis(181,182).  
 
Various medications were investigated regarding their effects in the levels of circulating 
microparticles in diabetes. Apart from the antidiabetic drugs, anti-hypertensives, statins and 
anti-platelets have been demonstrated to decrease the microparticles in various populations 
with diabetes (Table 7) (183).  
 
(Table 6) 
 
(Table 7) 
 
5.3 Smoking 
 
Smokers have significantly higher levels of plasma tissue factor concentrations(205). Human 
monocytes and macrophages produce microparticles and demonstrated apoptotic activity in 
vitro, after exposure to tobacco smoking extract. These microparticles were found to be tissue 
factor positive, reflecting their procoagulant properties(206). 
 
Smokers with normal spirometry but reduced diffusing capacity of the lung for carbon 
monoxide have also elevated levels of endothelial derived microparticles, likely derived from 
apoptotic endothelial capillary cells(207). Another mechanism which appears to be induced 
by tobacco smoke inhalation is microparticle gelatinolytic and collagenolytic activities. After 
exposure to tobacco smoking extract in vitro, human macrophages produce microparticles 
with transmembrane matrix metalloproteinase 14 (MMP14). These microparticles may 
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mediate extracellular matrix destruction leading to  inflammation, atherosclerotic plaque 
vulnerability and tissue necrosis(208). Elevation of endothelial derived microparticles was 
also observed in passive smokers along with endothelial dysfunction, as assessed by flow-
mediated dilation using ultrasound. In the same study, the endothelial progenitor chemotaxis 
toward vascular endothelial growth factor was impaired resulting in reduction of nitric oxide 
production and endothelial dysfunction(209).   
 
5.4 Dyslipidaemias 
 
Endothelial derived microparticles were found to be elevated in patients with uncomplicated 
type 2 diabetes mellitus after consumption of high-fat meals. This elevation was correlated 
with other dysmetabolic changes such as high levels of glucose, insulin, and triglycerides and 
low levels of high density lipoprotein(210). Hypercholesterolaemia along with endothelial 
derived microparticles has inhibitory activity in cardiac angiogenetic mechanisms through 
imbalance of the endothelial nitric oxide synthetase regulation(211). Hypercholesterolaemic 
conditions may induced endothelial damage associated with microparticles but there is 
evidence that can also promote generation of prothrombotic vesicles.  Aggregated low 
density lipoprotein was found to induce release of tissue factor positive microparticles from 
human vascular smooth muscle cells(212). Similarly, monocytes enriched by cholesterol in 
vitro, appear to expose phosphatidylserine on their cellular membrane along with induction of 
apoptosis and release increased levels of tissue factor positive microparticles(213). 
Additionally, phosphatidylserine expression mediated by oxidative low density lipoprotein in 
diabetic population  was associated with elevated levels of platelet derived 
microparticles(214).  
 
The relation between the endothelial protective role of high density lipoprotein and 
microparticles has been investigated(43,215). High density lipoprotein was reported to inhibit 
the binding of the T cell derived microparticles to monocytes and sequelae monocyte 
activation. Furthermore, high density lipoprotein partially inhibited production of pro-
inflammatory cytokines from monocytes .  
 
In several studies which recruited patients with type 2 diabetes  and hyperlipidaemias (Table 
5) there was a reduction of the circulating microparticles after treatment with statins. For 
example, in patients with type 1 diabetes mellitus and hyperlipidaemia, treatment with 
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atorvastatin reduced gpIIIa, P-selectin- and tissue factor-containing microparticles(197). For 
patients with type 2 diabetes and hyperlipidaemia, treatment with pravastatin for 8 weeks did 
not alter significantly the blood cholesterol concentrations but reduced the gpIIb/IIIa 
membrane receptor in the circulating platelet derived microparticles. GpIIb/IIIa is an 
important receptor for fibrinogen involved in thrombus formation. Downregulation of this 
receptor which is possibly induced by changes to platelets and microparticles lipids 
membrane composition might contribute to less thrombotic risk(71). Fluvastatin reduced 
microparticles in vitro from cultured human coronary artery endothelial cells by inhibition of 
the Rho kinase pathway which is responsible for alteration of cytoskeleton(216).  
 
High triglycerides levels is a component of metabolic syndrome among with 
hyperinsulineamia, hypertension and low high-density lipoprotein cholesterol levels(217). 
Elevation of endothelial(218), platelet(219) and leukocytes derived microparticles(220) in 
patients with metabolic syndrome contribute to vascular inflammation and hypercoagulant 
status which promote atherosclerosis and thrombosis(141). In an observational study(221) 
participating patients with metabolic syndrome, dyslipidaemia was associated with higher 
levels of endothelial derived microparticle (CD144+) and erythrocyte microparticle 
(CD235a+) compared with healthy control group. Obesity influenced the levels of platelet 
(GpIIb/IIIa+) and endothelial derived microparticles and hypertension only the endothelial 
derived microparticles. Levels of AnnexinV+ microparticles were affected by each of the 
different components of metabolic syndrome.  
 
 
6. Microparticles and cardiovascular diseases 
 
6.1 Atherosclerosis 
 
Various mechanisms contributing to initiation, progression and clinical manifestation of 
atherosclerotic disease are associated with the presence and formation of microparticles 
(Figure 5). The disruption of the normal levels and composition of the microparticles might 
represent one of the initial steps of the atherosclerotic disease. The link between apoptosis 
and microparticle production is well-established(142). Reduced laminar shear stress is also 
reported as a signal for endothelial apoptosis(222) which potentially contributes to 
microparticle production and imbalance of the normal endothelial features(223).   
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Endothelial permeability occurs during the first phase of the atherosclerotic process(224). 
Findings suggest a link between endothelial permeability and microparticles.  Injection of 
endothelial derived microparticles in rats significantly increases the pulmonary capillary 
permeability and causes acute lung injury. This action is likely mediated through inhibition of 
nitric oxide generation and sequelae impaired vasodilation(225). Abnormal endothelial 
homeostasis related with nitric oxide production have been reported with endothelial derived 
microparticles(136) and T lymphocyte-derived microparticles in vitro(138). Another 
mechanism, mediated by CD54, might play a role in atherogenesis. It was described in 
patients with multiple sclerosis where endothelial derived microparticle CD54+ induce 
inflammation and increase migration of monocytes through the endothelium(226). 
Additionally, platelet derived microparticles can affect the endothelial cell barrier integrity, in 
a manner related with their size and protein composition(227).  
 
Chemo-attraction of leukocytes to the inflamed endothelial segment is essential for the 
progression of atherosclerosis(228). Microparticles from different cellular origins may trigger 
production of pro-inflammatory cytokines from the endothelium, such as IL-6 and IL-8, 
which attract and activate leukocytes(95,229). Another suggested mechanism which 
contributes to the progression of the atheroma is linked to microparticles-induced expression 
of adhesion molecules on the endothelial cells. An example is platelet derived microparticles 
mediated upregulation of intercellular adhesion molecule-1 on the endothelial cell 
membrane(95,230). Plaque microparticles isolated from endarterectomy specimens could 
transfer ICAM-1 to endothelium(231). Also microparticles induce integrin expression on the 
surface of the leukocytes, such as CD11a and CD11b,  which interact with intercellular 
adhesion molecule-1(95). Chemokines delivered from microparticles to inflamed or 
atherosclerotic endothelium promote further leukocyte recruitment. Mause et al described a 
platelet derived microparticle-associated delivery of the chemokine RANTES (regulated on 
activation, normal T cell expressed and secreted) to human microvascular endothelial cells 
which promotes monocyte adhesion(89).  
 
Microparticles concentrations are 200 times higher in atherosclerotic plaques than in 
blood(232). Microparticles derived from leukocytes have the higher levels in plaques; 29% 
found to be from macrophages, 15% from lymphocytes and 8% from neutrophils. Other 
significant populations of microparticles concentration delivered from erythrocytes (27%), 
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smooth muscle (13 %) and endothelial cells (8%)(232).  Microparticle origin in 
atherosclerotic plaques was not found to be affected by symptoms of ischaemia(232). All 
plaque microparticles, regardless their origin, possess pro-coagulant activity as they express 
tissue factor on their external plasma membrane surface(233).  
 
Furthermore, atherosclerotic plaques microparticles was described that contain 
immunoglobulins. The immunoglobulins they expressed were found to be different from the 
plasma circulating microparticles(234). Co-labelling of IgG and CD14 demonstrated that the 
vast majority of microparticles (93±7%) containing IgG were CD14+, revealing their 
macrophage origin(234). High macrophage infiltration was observed also in raptured 
atherosclerotic lesions with concurrent macrophage apoptosis(235). Microparticles are 
involved in macrophage apoptosis but is unknown if this mechanism contributes to rapture or 
characterise vulnerability of the fibrous cap of the atheromatous plaques(236). Additionally, 
as macrophages have been involved in the clearance of microparticles, defective 
phagocytosis due to increased macrophage apoptosis may lead to accumulation of 
microparticles(237–239). A point towards this hypothesis is the acceleration of 
atherosclerotic lesions in mice which lack lactadherin activity(240). Lactadherin is essential 
protein for the removal of the microparticles(241).  
 
Atherosclerosis is a complex immune-inflammatory disease which several type of cells are 
involved, including lymphocytes (T, B, Natural killer T), dendritic cells, and mast cells(242). 
In vitro, endothelial derived microparticles induced dendritic cell maturation and secretion of 
pro-inflammatory cytokines, contributing to CD4 T cells activation and proliferation(243). In 
the same study, microparticles from activated T cells or platelets failed to stimulate dendritic 
cell maturation(243). Polymorphonuclear neutrophil-derived microparticles were reported to 
interact with human monocyte-derived dendritic cells and to promote morphologic changes 
which reduce monocyte phagocytic activity and increase cytokines excretion(244). 
Additionally, microparticles from activated dendritic cells can interfere with resting dendritic 
cells and transfer antigens to them(245). These antigens can be presented to lymphocytes 
leading to their activation and proliferation(245). Microparticles from T cells may also 
stimulate mast cells. This action can take place by transfer of membrane biomolecules via 
microparticles instead of cellular contact(246).  
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Smooth muscle cell proliferation and migration from the media to intima is essential for the 
formation of the atheroma(228). Platelet derived microparticles were found to have mitogenic 
effect on smooth muscle cell in vitro, with no chemotactic contribution(247). The mitogenic 
effect increased synergically if platelet derived microparticles were combined with serotonin 
or thromboxane A2(248). The chemotaxis for smooth muscle cell migration is strongly 
mediated by tissue factor receptors(249,250). Microparticles isolated from atherosclerotic 
plaques express tissue factor in their surface(233) and might act as a chemo-attractive factor 
for smooth muscle cell  migration and proliferation.  
 
The intraplaque neovessel formation due to hypoxia and inflammation influences the stability 
of the atherosclerotic lesion(251,252). Microparticles might play a significant role in the 
neovascularization. They can carry proteolytic enzymes on their membrane and they have 
ability to induce the production of metalloproteases from other cells, so the endothelial tissue 
would be able to penetrate the surrounding interstitial matrix(253–255). Furthermore, plaque 
microparticles mainly of macrophage origin can induce endothelial cell proliferation in 
vivo(256). On the contrary, in this study circulating microparticles were unable to induce 
endothelial cell proliferation(256). CD40/CD40 ligand system appears to play an important 
role in the microparticles endothelial cell interaction(256). Patients with symptoms of cardiac 
ischaemia expressed more CD40L than asymptomatic patients and their microparticles were 
more potent endothelial proliferation inducers in vitro(256).  
 
Studies of patients with early atherosclerosis and chronic coronary artery disease showed 
increased levels of CD144+/CD31+ endothelial derived microparticles expressing T-cadherin 
compared with healthy volunteers. T-cadherin was found to reflect endothelial dysfunction as 
measured by reactive hyperaemia following brief peripheral flow occlusion(257). Plasma 
levels of CD144+/ CD42b- endothelial derived microparticles predicted the presence of 
coronary artery disease in asymptomatic diabetic patients (258). 
 
6.1.1 Acute coronary syndromes 
 
In the setting of acute coronary syndromes, the most studied microparticles are platelet 
derived microparticles and endothelial derived microparticles.  Observational studies showed 
increased levels of CD146+ and CD31+ endothelial derived microparticles (Table 8) in 
patients with acute coronary syndrome compared to patients with stable angina or with no 
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coronary artery disease(259,260). Acute coronary syndromes are associated with raised 
thrombotic activity. Morel et al described that patients with ST elevation myocardial 
infarction and unstable angina had higher levels of procoagulant microparticles compared 
with patients with stable angina. The principal population of procoagulant circulating 
microparticles were platelet derived microparticles GPIb+ and endothelial derived 
microparticles CD31+(261). The majority of endothelial derived microparticles expressed the 
pro-atherogenic adhesion molecule, vascular cell adhesion molecule-1 (VCAM-1)(262). 
 
Revascularization affects the levels of the circulating microparticles as reduces the 
endothelial injury. In a cross-sectional study, a significant reduction in Annexin V-binding 
and endothelial microparticles observed after primary percutaneous coronary intervention 
(PCI) in ST elevation myocardial infarction patients, compared to patients with stable 
coronary artery disease or non- ST elevation myocardial infarction before PCI(263). Zhou et 
al(264) investigated the levels of three groups of microparticles (endothelial derived 
microparticles CD144+, platelet derived microparticles CD41+ and leukocyte-derived 
microparticles CD45+) during the acute phase of ST elevation myocardial infarction /primary 
PCI and 48 hours later. Platelet derived microparticles increased immediately post PCI and 
reached the maximum levels 48 hours later. Endothelial derived microparticles and CD45+ 
microparticles decreased immediately post PCI and gradually increased up to 48 hours 
later(264). Abciximab, an GPIIb-IIIa antagonist, in combination with primary coronary 
angioplasty reduces the level of platelet derived microparticles compared with patients that 
had only percutaneous angioplasty(261). Failure of revascularisation strategy, such as 
thrombolysis, induced higher levels of procoagulant microparticles (tissue factor + 
microparticles)(265).  
 
Differences were also detected in the levels of circulating annexin V+ and tissue factor+ 
microparticles as regard the vascular level of origin. Microparticles were elevated in the 
culprit artery compared with the peripheral blood in patients with ST elevation myocardial 
infarction after primary percutaneous coronary intervention, suggesting local vascular 
damage(266,267).  
 
Biasucci et al(268) demonstrated a relation between high-sensitivity C-reactive protein (hs-
CRP) endothelial and platelet derived microparticles levels in patients with stable coronary 
artery disease and acute coronary syndrome. The annexin V+ microparticles were related to 
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the troponin T levels and the degree of myocardial injury. No significant differences were 
detected regarding type of acute coronary syndrome (Non ST elevation myocardial infarction 
vs ST elevation myocardial infarction) and the levels of circulating microparticles(268). 
Endothelial derived microparticles and platelet derived microparticles were also found to be 
related with the extension of the MI(269).  
 
(Table 8) 
 
6.1.2 Peripheral vascular disease and ischaemic stroke 
 
Endothelial derived microparticles were found to be elevated in patients with peripheral 
arterial disease and particularly microparticles expressing the monomeric CRP molecule on 
their membrane, suggesting the inflammatory nature of the condition(271). High levels of 
leukocyte derived microparticles (CD11a+) were also found in patients with non-
symptomatic atherosclerotic disease demonstrated by ultrasound examination of carotid, 
abdominal aorta, and femoral arteries(272). Leukocyte (CD11a+) along with endothelial 
derived microparticles (CD105+) observed to be associated with higher carotid intima-media 
thickness in patients before atherosclerotic disease is evident(273).  Platelet derived 
microparticles (CD63+) were  also raised in patients with peripheral arterial disease with or 
without  myocardial infraction(274) and after bypass grafting, reflecting the thrombotic 
nature of the disease. Certain cytokines such as IL-6, G-CSF and thrombopoietin were also 
detected to be high in patients with peripheral arterial disease and may related with 
microparticle formation from platelets(275).  
 
Patients with recent ischaemic stroke were found to have higher levels of CD62E+ 
endothelial derived microparticles. More severe strokes, classified by National Institute of 
Health Stroke Scale score, were associated with higher CD62E+ endothelial derived 
microparticle levels, reflecting the severity of the endothelial damage and the degree of 
endothelial activation. From the same study, patients without stroke but with significant risk 
factors for atherogenesis and extracranial arterial disease had higher CD62E+ endothelial 
derived microparticle levels, in contrast to patients with intracranial arterial stenosis where 
the CD31+/CD42b- and CD31+/Annexin V+ endothelial derived microparticle subpopulation 
levels were raised(276). Simak et al(277) investigated the levels of endothelial derived 
microparticles in acute stroke patients using flow cytometry. Endoglin-positive endothelial 
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derived microparticles (CD105+/CD41a-/CD45-), endothelial derived microparticles 
expressing VE-cadherin and endoglin(CD105+/CD144+), 
phosphatidylserine(CD105+/phosphatidylserine+/CD41a-) and Intercellular Adhesion 
Molecule-1(CD105+/CD54+/CD45-) were analysed. Only phosphatidylserine+ endothelial 
derived microparticles were significantly higher in the acute stroke group compared with the 
control. All the endothelial derived microparticles subtypes were elevated in patients 
suffering moderate to severe stroke (according to National Institutes of Health Stroke Scale). 
Significantly elevated Endogline and Intercellular Adhesion Molecule-1 positive endothelial 
derived microparticles on admission were associated with worse prognosis. Apart from 
endothelial derived microparticles, patients with acute ischaemic stroke were found to have 
increased levels of platelet derived microparticles (GpIIIa+) during the acute phase and up to 
6 months later, compared with healthy controls(278), suggesting that thrombotic tendency 
might last more than the acute phase of the infarct. 
 
6.2 Heart failure 
 
For patients with non-ST elevation myocardial infarction, elevated endothelial derived 
microparticles and monocyte derived microparticles were associated with higher readmission 
rates from heart failure (Table 9)(263).  Different factors may affect the levels and the origin 
of microparticles in heart failure patients. Endothelial derived 
microparticles(CD31+/Annexin V+) were higher in patients with 3 vessel coronary artery 
disease and Heart failure with reduced ejection fraction compared with patients with same 
degree of coronary artery disease but preserved Left Ventricular systolic function(279). The 
same type of microparticles were higher in patients with heart failure with reduced left 
ventricular ejection fraction and increased Body Mass Index (BMI>25kg/m
2
) compared with 
other patients with lower BMI(280). Apoptotic annexin V+ microparticles were found to be 
elevated in heart failure patients with worse functional status (dyspnoea class III-IV of New 
York Heart Association scale)(281).  
 
Subjects with heart failure and preserved left ventricular ejection fraction were found to have 
lower ratio of CD31+/annexin V+ endothelial derived microparticles to Endothelial 
progenitor cells (as expressed by CD14+/CD309+ and CD14+/CD309+/Tie-2+) in 
comparison with Heart failure with reduced ejection fraction patients. That ratio in 
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combination with pro-BNP levels was demonstrated to have good discriminatory value 
between heart failure with reduced and preserved ejection fraction(62). 
 
Few studies were conducted to assess the differences of various microparticles levels among 
patients with end stage heart failure requiring left ventricular assisting devices or heart 
transplantation. From  an observational study(282), heart transplant patients were compared 
with heart failure patients and healthy controls regarding the levels of endothelial derived 
microparticles (CD62 E+ and CD31+). Heart failure patients had higher numbers of CD62+ 
endothelial derived microparticles compared with healthy and post-transplant patients. 
Apoptotic microparticles, based by the ratio of CD62E/CD31 (apoptosis=low ratio), were 
higher in transplant patients. More microparticle populations investigated in a study that 
enrolled heart failure patients, patients with left ventricular assisting devices and patients post 
heart transplant. Left ventricular assisting devices were associated with elevated levels of all 
microparticles types suggesting erythrocyte destruction and endothelial activation. In patients 
with heart transplant post left ventricular assisting devices, all microparticles levels were 
decreased(68). The endothelial damage, as expressed with phosphatidylserine+ 
microparticles, 3 months post left ventricular assisting device implantation, demonstrated to 
be lower compared to pre-implant period in heart failure patients, regardless the aetiology of 
heart failure(283).  
 
Patients with congestive heart failure and metabolic syndrome was demonstrated to have 
higher levels of CD31+/Annexin V+ endothelial derived microparticles in addition with 
lower levels of CD62E+ endothelial derived microparticles compared with healthy subjects. 
The ratio of CD62E+ to CD31+/Annexin V+ endothelial derived microparticles was 
significantly lower among the patients with heart failure and metabolic syndrome in contrast 
to patients with metabolic syndrome but without heart failure and healthy subjects(66).  
 
(Table 9) 
 
6.3 Atrial Fibrillation 
 
Patients with atrial fibrillation have increased risk of ischaemic stroke and were found to 
have higher levels of platelet derived microparticles (CD42b+/CD61+) in contrast with 
healthy subjects. There was no difference in the levels of circulating platelet derived 
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patients on treatment with aspirin or warfarin. In the same study there were no significant 
differences in platelet derived microparticles for patients in atrial fibrillation and patients 
with established coronary artery disease and sinus rhythm(285).  In another observational 
study, Annexin V+ microparticle levels were higher in atrial fibrillation patients compare 
with healthy controls and with patients with sinus rhythm but cardiovascular risk factors 
(disease control). On the contrary, platelet derived microparticles (anti-glycoprotein Ib+) and 
endothelial derived microparticles (CD31+) were similar in patients with AF and disease 
control group but higher compared with healthy control subjects(286).  
 
In  patients with chronic AF due to mitral stenosis CD41+ platelet derived microparticles 
levels were higher compared to healthy controls and there was a significant direct 
relationship between the mitral valve area and the levels of circulating platelet derived 
microparticles(287), suggesting  higher risk of thromboembolic events with increasing 
severity of mitral stenosis. 
 
Induction of AF during electrophysiology studies increased the P-selectin+ microparticles 
compared with chronic AF and control patients which might reflect different procoagulant 
mechanism between chronic and paroxysmal AF(288).  
 
6.4 Pulmonary Hypertension 
 
Diehl et al(289) reported increased levels platelet (CD31+/CD61+), Leukocyte (CD11b+) 
and endothelial derived microparticles(CD62E+) in pulmonary hypertensive patients 
compared with healthy subjects, suggesting that the mechanisms which are involved in the 
progression of the disease are associated with platelet activation, inflammation and 
endothelial dysfunction(289). In another study(290), several types of microparticles [platelet 
(CD31+/CD41+), endothelial(CD62E +, CD144+, CD31+/ CD41-), leukocyte (CD45+) and 
apoptotic (annexin V +) microparticles] were analysed from patients with precapillary 
pulmonary hypertension before any treatment with endothelium-active vasodilator therapy. 
Endothelial and leukocytes derived microparticles levels were higher among pulmonary 
hypertension patients compared to healthy control group. CD31+ and CD144+ microparticles 
levels were strongly associated with the haemodynamic severity of the disease.  
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Results from an observational study(291) with paediatric patients and Eisenmenger syndrome 
suggested that CD144+ endothelial derived microparticles along with the thickness of 
pulmonary artery intima media and pulmonary stiffness can be used as non-invasive 
alternative tests to monitor the progression of the disease.  Lin et al(292) also reported 
elevated endothelial derived microparticles (CD31+/ CD42b-) in adult patients with 
pulmonary hypertension secondary to atrial or ventricular septal defect.  
 
A possible link between endothelial derived microparticles and increased phosphorylation of 
the P38 mitogen-activated protein kinases, was demonstrated in a rat model, which can 
induce inflammatory process along with impaired function of endothelial NO synthetase. 
Endothelial derived microparticles (endoglin+) from rats with advanced pulmonary 
hypertension can induce expression of Intercellular Adhesion Molecule-1 in pulmonary 
artery endothelial cells and Intercellular Adhesion Molecule-1 can promote 
inflammation(293). Endoglin+ microparticles were also found to be elevated in patients with 
pulmonary hypertension due to chronic thromboembolic disease compared to healthy control 
subjects. This might represent a protective/reactive  mechanism as in vitro endoglin promoted 
angiogenesis and increased the life of cultured endothelial cells(294).     
 
 
7. Prognostic value of microparticles 
 
Several studies have demonstrated an association between microparticles and outcomes in 
patients with cardiovascular diseases(Table 10). Coronary artery disease is the most studied 
condition. From an observational study that recruited patients with cardiovascular risk factors 
and stable coronary artery disease, CD31+/annexin V+ microparticles (apoptotic endothelial 
& platelet derived microparticles) levels were correlated with higher risk of major adverse 
cardiovascular and cerebrovascular events and the need for revascularization(295). In patients 
with ST elevation myocardial infarction post primary angioplasty, high levels of monocyte 
derived microparticles were strongly related with poor long term survival(296). Additionally, 
post angioplasty levels of erythrocyte derived microparticles in ST elevation myocardial 
infarction patients were higher compared to healthy individuals and associated with higher 
risk of major adverse cardiovascular and cerebrovascular events(297). Increased tissue 
factor+ microparticle levels were also related with poor outcomes in patients with acute 
coronary syndrome (unstable angina or acute MI)(298). 
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Montoro-Garcia et al(263) reported that in patients with non-ST elevation myocardial 
infarction, levels of endothelial and monocyte derived microparticles were associated with a 
higher risk of future admissions due to left ventricular failure and levels of platelet derived 
microparticles with a higher risk of major haemorrhagic events(263). Higher counts of 
endothelial derived microparticles were also associated with worse outcomes in patients who 
presented with cardiac sounding chest pain and underwent coronary angiography for further 
evaluation(299). 
 
Apart from coronary artery disease, several studies reported association between 
microparticles and outcomes for patients with heart failure. In acute decompensated heart 
failure due to coronary artery disease the levels of endothelial derived microparticles 
(CD31+/Annexin V+) were related with increased mortality within the 3-year follow up 
period(300). Bulut et al(279) reported similar findings in patients with ischaemic 
cardiomyopathy. The ratio of endothelial progenitor cells to endothelial derived 
microparticles (CD31+/Annexin V+) was decreased in the cardiomyopathy group compared 
with patients with stable 3 vessel coronary artery disease and preserved left ventricular 
systolic function, suggesting that apart from endothelial dysfunction there is impaired 
vascular repair capacity. Worse outcomes were also described in patients with left ventricular 
assisting devices and elevated phosphatidylserine/Annexin V+ microparticles(301). Finally, 
patients with pre-capillary pulmonary hypertension prior to treatment, high levels of CD62E+ 
endothelial derived microparticles were associated with higher risk of death and 
hospitalization due to right heart failure(302).  
 
(Table 10) 
 
8. Conclusion 
 
Microparticles appear to be key players in important biological functions and to have 
fundamental role in many cardiovascular pathophysiological mechanisms. Abnormal 
production of microparticles as result of different risk factors leads to inflammation, 
thrombosis and endothelial damage (Figure 6). The consequences of these pathological 
processes is the manifestation of cardiovascular disorders. Alternative, microparticles may be 
generated due to various cardiovascular conditions and their levels reflect disease activity and 
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severity. As the knowledge of their functions expands, their role as biomarker is rising. 
Research data suggest that levels of microparticles also indicate prognosis. An important 
issue, however, is that there is no standardised analysis technique for microparticles which 
results in a large diversity of data. This makes difficult to compare results from different 
analyses and each study should be interpreted separately. Beyond that limitation, 
microparticles seem to move slowly from research towards clinical level. However, further 
research is needed in order to guide clinicians how to use microparticles as biomarkers in 
several cardiovascular diseases and tailor treatments according to individual response and 
prognosis.  
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Figure 1. Extracellular vesicles 
 
1: Production of microparticles after stimulation of paternal cell. Microparticles are released 
from activated cell after outwards rearrangement of the cellular membrane. 
2: Production of microparticles during apoptotic process. Microparticles are released before 
the formation of apoptotic bodies 
3: Endosomes in multivesicular body. After exocytosis of the endosomes into the 
extracellular environment may be called exosomes 
 
 
Figure 2. Mechanisms involved in the generation of the Microparticles 
 
1: After activation of the cell an increased Ca
+2 
influx follows.  
2: Externalisation of phosphatidylserine mediated by ATP-dependent floppases, scramblases 
and membrane pores 
3: Cytoskeleton Protein reconfiguration in order to produce outward membrane blebs.  
 
Capsases, caplains and Rho kinases are involved in the process 
 
 
Figure 3. Microparticle content 
 
External surface of plasma membrane in general contains negatively charged 
phosphatidylserine along with membrane proteins like major histocompatibility complex 
molecules, integrins and tissue factor. In the cytosol, there is no organised nucleus but apart 
from cytoskeleton proteins and enzymes, nucleic acid remnants (DNA or RNA) are present.  
 
 
Figure  4. Mechanisms and molecules related with Microparticle induced coagulation 
 
Abbreviations: PS phospatildylserine; GLA γ-carboxyglutamic acid; clotting proteins factors 
VII, IX, X, and prothrombin. 
 
Negatively charged PS electrostatically attract the positively charged segment of clotting 
proteins/GLA complex and induce thrombogenesis. Tissue factor may also activate the 
coagulation cascade via the FVII/VIIa complex. Additionally, inhibition of fibrinolysis by  
microparticle membrane proteins such as plasminogen activator inhibitor-1 and protein S 
may augment thrombogenesis.   
 
 
Figure 5. Mechanisms associated with initiation and progression of atherosclerosis 
mediated by Microparticles (MPs) 
 
 
Figure 6. Cardiovascular diseases and microparticles 
 
Flow chart which summarises the role of microparticles in the genesis (related with several 
risk factors)  and manifestation of cardiovascular diseases. Utilisation as biomarkers to assess 
disease activity/severity, prognosis and treatment guidance is emerging as detection and 
enumeration methods for microparticles are improving.  
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Table 1. Stimuli causing generation of microparticles in vitro or in vivo(37)(20) 
Type of cell Endothelial 
cell 
Platelet Neutrophil T-Cell Monocyte 
and Macrophage 
Smooth cell 
Stimuli       
 Modified LDL Flow conditions Pro-inflammatory  
cytokine
s 
Pro-inflammatory  
cytokines 
Cigarette extract Modified LDL 
 HDL cholesterol Thrombin  Phytohemagglutinin Pro-inflammatory  
cytokines 
HDL cholesterol 
 Uremic toxin Collagen Phorbol myristate 
acetate 
Staurosporin Calcimycin  
 Flow conditions Homocysteine  Etoposide  Flow conditions 
 Thrombin Pro-inflammatory  
cytokines 
Anti-neutrophil 
cytoplas
mic 
antibodie
s 
Actinomycin D Lipopolysaccharides Activated protein 
C 
 Homocysteine Calcimycin Bacterial 
infection 
Phorbol myristate 
acetate 
Etoposide Pro-inflammatory  
cytokine
s 
 Activated protein C collagen N-Formyl-
Methion
yl-
Leucyl-
Phenylal
anine 
 Fas Ligand Fas-ligand 
 Plasminogen 
activator 
inhibitor 
Lipopolysaccharides    Platelet derived 
growth 
factor 
 Pro-inflammatory  
cytokinesa 
Shiga toxin     
 Oxidative stress sCD40 Ligand     
 High glucose Erythropoietin     
 Uremic toxins Noradrenaline     
 Lipopolysaccharides acid phosphatase 5     
 Camptothecin Reactive oxygen 
species 
    
 Angiotensin II      
 Plasminogen 
Activator 
Inhibitor 1 
     
 C Reactive Protein      
a: tumor necrosis factor a, Interleukin 1b, Interleukin 6,  
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Table 2. Main antigen markers used for MP cell 
origin determination 
Cell Cluster of differentiation (CD) 
Endothelial CD31(59) 
 CD51(60) 
 CD105(61) 
 CD62E(61) 
 CD144(62) 
 CD34(63) 
Platelet CD41(64) 
 CD42a(65) 
 CD42b(66) 
 CD61(63) 
Red Cell CD235(67) 
Leukocyte CD45(67) 
Monocyte CD14(68) 
Neutrophil CD66b(64) 
T cell CD4(69) 
 CD8(70) 
CD31, CD51, CD105 are not specific for endothelial cells. CD31 is 
also expressed on platelets, CD51 on platelets and 
macrophages and CD105 in activated 
monocytes/macrophages. For MP detection, markers are 
usually combined to discriminate this population from other 
MPs. For example, platelet MPs are CD31 positive / CD42b 
positive whereas endothelial MPs are CD31 positive / 
CD42b negative. 
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Table 3. Bioactive molecules of microparticles  
Molecule Type of cell producing 
Microparticles 
Target cell or environment 
Receptor/Membrane molecule   
chemokine receptor CCR5(74) peripheral blood mononuclear cells Various cells 
CXCR4 receptor(82)(83) Platelets Various cells 
Glycoprotein IIb/IIIa receptors(84) Platelets neutrophils 
oncogenic receptor EGFRvIII (epidermal 
growth factor receptor variant III) (85) 
Tumor Cells Various cells 
major histocompatibility complex (MHC) 
class II(73) 
Immune cells Immune cells 
Tissue Factor(48) Monocytes Platelets 
Peroxisome proliferator-activated receptor 
gamma(86) 
Platelets Monocytes 
Cytokines   
interleukin-1beta(87)(76)(75)(88)  Various cells Various cells 
Chemokine (C-C motif) ligand 5(89) Platelets   Endothelial cells 
Growth factors   
Vascular endothelial growth 
factor(90)(91)(92) 
Platelets/Tumor Cells Endothelial cells 
Basic fibroblast growth factor(90)(91) Platelets/Tumor Cells Endothelial cells 
Platelet-derived growth factor(91) Platelets Endothelial cells 
Lysis enzymes   
Matrix metalloproteinases(92) Tumor Cells extracellular matrix 
Extracellular matrix metalloproteinase 
inducer(93) 
Tumor Cells extracellular matrix 
Caspase 1(94) Monocyte Smooth muscle cell 
Lipids   
Arachidonic acid(79)(80)(95) Platelets Various cells 
Platelet activated factor(96)(97) Various cells Platelets 
Ribonucleic acid (RNA)   
Messenger  RNA(98)(38)  Stem cells Various cells 
Micro RNA(99)(100)(101) Stem cells Various cells 
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Table 4. Inflammation and Microparticles (MPs) 
Type of cell producing MPs Target cell  Molecules involved in the pathogenesis of inflammation 
mediated by MPs 
  Cytokines 
Endothelial Various inflammatory cells IL-1β and TNF-α(114) 
Leucocytes 
 
Endothelial IL-6 and MCP-1(115) 
T cells monocytes IL-8, TNF-a and IL-1β(43)(116) 
  Adhesion molecules 
Monocytes  
Platelet  
 
endothelial intercellular adhesion molecule-1,  
vascular cell adhesion molecule-1 
 E-selectin(117)(95) 
  lipids 
Platelet endothelial thromboxane A2 and cyclooxygenase(79) 
  Other 
Polymorphonuclear macrophage transforming growth factor beta1(118) 
  Annexin V(119) 
Monocytes  macrophage peroxisome proliferator-activated receptor gamma 
protein(120) 
Polymorphonuclear  Various cells complement proteins (C1q)(51) 
Abbreviations: IL interleukin, TNF tumor necrosis factor, MCP-1 Monocyte chemoattractant protein-1,  
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Table 5. Angiogenesis and Microparticles (MPs) 
Type of cell producing 
MPs 
Target cell or environment Molecules involved in the 
angiogenesis mediated by MPs 
Promotion of neovascularisation 
Platelets Human umbilical vein 
endothelial cells 
bioactive lipids(90)(121) 
Platelets Ischaemic myocardium vascular endothelial growth factor 
(VEGF),  
basic fibroblast growth factor 
(BFGF), 
inhibition of platelet factor-4(91) 
Various cells expressing 
membrane Tissue Factor 
Endothelial beta1-integrin, 
extracellular signal regulated 
kinase(122) 
T-cells Endothelial Activation of morphogen Sonic 
Hedgehog (Shh) pathway which 
promotes synthesis of adhesion 
molecules and proangiogenic 
factors(123)(124) 
 
Endothelial Endothelial  Plasmin activating factors(125) 
 
Endothelial Matrix metalloproteinases(126) 
Endothelial  endothelial Messenger RNA(127) 
Adipose cells Human umbilical vein 
endothelial cells 
Leptin, fibroblast growth factor 
alpha (FGFa), Tumor Necrosis 
Factor a, matrix metalloprotease 
(MMP)-2 and MMP-9 mediated 
activation(128) 
Inhibition of neovascularisation 
Lymphocyte Endothelial CD36 antiangiogenic 
receptor(132) 
Abbreviations: CD cluster of differentiation, RNA Ribonucleic acid 
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Table 6. Studies with Microparticles (MPs) in Diabetic populations or high glucose 
concentration conditions 
Type of MPs Conclusion Reference 
Endothelial derived microparticles 
CD62E positive, CD62P positive, 
CD142 positive, CD45 
positive circulating MPs, their 
apoptotic (AnnexinV positive) 
fractions  and miRNA-126 
expression. 
 
CD62E positive MPs level 
and miR-126-3p content in 
MPs are abnormal in 
subjects with pre-diabetes.  
 
Giannella A et al(163) 
CD3 positive T- Lymphocyte MPs, 
CD105 positive EMPs, Annexin V 
positive MPs, CD31 positive MPs, 
CD41a positive and Annexin 
V/CD31/ CD41a positive 
Increased number of MPs in 
diabetic patients compare 
with healthy control group 
Kurtzman N et al. (164) 
PMPs   Association with vascular 
changes in T2DM/ 
endothelial dysfunction and 
activated platelets/PMPs 
Nomura S et al.(166) 
Μonocytes derived MPs Annexin 
V/CD14 positive, PMPs GPI 
positive 
higher in diabetic patients of  
with related vascular 
complications 
Omoto S et al(167) 
annexinV positive, PMP 
CD31/CD42 positive, LMP 
CD45positive , 
CD31positive/CD42negative EMP,  
CD51positive EMP 
MPs increased in patients 
with T2DM. EMPs levels 
are associated with vascular 
dysfunction. 
Feng B et al(61) 
CD36 positive CD 36 positive MPs in DM 
patients were from 
erythrocyte origin compare 
with healthy subjects, 
originated from endothelial 
cells.  
Alkhatatbeh MJ et 
al(168) 
PMPs CD41 positive, EMPs CD51 
positive, leukocytes derived MPs 
CD45 positive, neutrophil derived 
MPs CD66b positive, monocyte 
derived MPs CD14 positive and 
total annexin V-positive MPs. 
Different phenotypes 
identified between T1, T2 
DM and healthy subjects. 
Differences in properties and 
particularly the procoagulant 
activities. 
Sabatier F et al(65) 
Annexin V positive, MPs from 
non- activated platelet 
(CD41positive), MPs from 
activated platelets (CD62p 
positive), EMPs (CD144 positive) 
MPs properties and type 
(composition, content and 
cellular origin) are related 
with the type of vascular 
complications due to DM. 
Tsimerman G et al(173) 
MPs from Human umbilical vein 
endothelial cells 
Raised glucose levels is a 
potent stimulus for MP 
formation that affects their 
molecular composition and 
may cause endothelial injury 
Burger et al. (172) 
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PMPs CD41 positive, Annexin V 
MPs, MPs expressing tissue factor 
(CD142) 
DM is associated with high 
levels circulating MPs with 
procoagulant features 
Tripodi A et al(174) 
EMPs CD144 positive, PMPs 
CD42b positive, monocyte derived 
MPs CD14 positive 
MPs from T1DM patients 
promoted 
platelet/endothelial cell 
interaction with an intensity 
correlated with the degree of 
the associated vascular 
complications 
Terrisse Ad et al(67) 
Lymphocyte and plasma MPs 
(Surface markers: CD3, CD11a, 
GP1b, CD31) 
Lymphocyte-derived MPs 
from diabetic patients or in 
vivo circulating MPs from 
diabetic patients reduced 
endothelial NO synthase 
expression. 
Martin S(138) 
Surface markers: CD41a, CD64, 
CD144, CD144/CD31, Annexin V, 
CD144/annexin V and 
CD144/CD31/annexin V.  
 
Apoptotic endothelial cell-
derived were significantly 
increased in diabetic patients 
and associated with 
asymptomatic 
atherosclerosis 
 
 
Berezin et al. (178) 
human coronary endothelial cells 
derived MPs 
High glucose environment 
increases NADPH oxidase 
activity in EMPs and 
promotes endothelial 
dysfunction 
Jansen F et al(177) 
EMPs (surface markers: CD31, 
CD42b, annexin V, and CD62E) 
EMP levels are associated 
with different risk of 
diabetic vascular 
complications 
Jung K-H et al(60) 
PMPs CD41 (GPIIb) positive, 
EMPs CD144 (VE-Cadherin) 
positive 
Unstable coronary artery 
plaques in diabetics are 
associated with elevated 
EMPs 
Bernard S et al(63) 
PMPs (Surface marker: antiplatelet 
GPIX monoclonal antibody) 
Plasma PMPs are 
significantly higher in 
patient with DM compare 
with normal controls. 
Antiplatelet therapy reduces 
the level of PMPs. 
Omoto S et al(169) 
EMPs CD 144 positive, Monocyte 
derived MPs CD 14 positive,  
PMPs tissue factor and CD 41 
positive 
Normalisation of glycaemic 
control in DM patients after 
bariatric surgery leads to 
reduction of the MPs levels 
Cheng V et al(69) 
PMPs, T-lymphocytes derived MPs 
and leukocyte derived MPs 
TF on MPs from DM 
patients may be involved in 
Diamant M et al(70) 
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(surface markers: quadruple-
stained with annexin V, CD61, 
anti-TF, and CD15 (ligand for P-
selectin), CD66e (granulocytic 
marker), or CD62P (P-selectin), or 
with CD4 (T-lymphocytes), anti-
TF, and CD11b (leukocyte marker) 
processes other than 
coagulation such as 
angiogenesis 
TF bearing MPs from human renal 
mesangial cells and human dermal 
microvascular endothelial cells 
MPs expressing TF might be 
a mediator to 
neovascularisation due to 
elevated glucose levels 
Ettelaie C et al(179) 
MPs from Human umbilical vein 
endothelial cells 
Reduction of miR-126 from 
plasma vesicles might 
explain the impaired neo-
angiogenesis in DM patients 
Zampetaki A et al(181) 
CD cluster of differentiation, EMP endothelial derived MP, PMP platelet derived MP, T2DM 
Type 2 diabetes mellitus, , GP glycoprotein, LMP leukocyte derived MP, TF Tissue factor, 
miR micro Ribonucleic acid, NADPH Nicotinamide adenine dinucleotide phosphate, NO 
Nitric monoxide 
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Table 7. List of medications induced reduction of Micproparticle (MP) levels in diabetic 
populations 
Medication 
category 
Pharmacological name Type of MPs 
investigated 
Other co-
morbidities apart 
from DM 
Antiplatelet Cilostazol(184) PMPs GPIX 
positive 
 
 Ticlopidine(185)(186)(187)  PMPs GPIX 
positive , 
Monocyte 
derived MPs 
CD14 positive 
Hyperlipidemia 
 Sarpogrelate(188) PMPs  
 Aspirin & Clopidogrel(189) PMPs CD151 
positive, 
Monocyte 
derived MPs 
CD14 positive 
TIA 
Antihypertensive Efonidipine(190) PMPs GPIX 
positive, 
Monocyte 
derived MPs 
CD14 positive 
HTN 
 Nifedipine(191),(192) PMPs GPIX 
positive, 
Monocyte 
derived MPs 
CD14/ Annexin 
V positive, EMPs 
CD51/ Annexin 
V positive 
HTN 
 Losartan(193)(194) PMPs GPIX 
positive, 
Monocyte 
derived MPs 
CD14/ Annexin 
V positive, EMPs 
CD51/ Annexin 
V positive 
HTN 
 Valsartan(195) Monocyte 
derived MPs 
CD14/ Annexin 
V positive 
HTN 
Anti-lipidaemic Pitavastatin(196) PMPs CD42b 
and CD42a 
(glycoprotein Ib 
and IX) positive 
Hyperlipidemia 
 Pravastatin(71) MPs derived 
from: platelets 
(CD61 positive), 
Hyperlipidemia 
Ac
ce
pt
ed
 M
an
us
cr
ipt
T-helper cells 
(CD4 positive), 
T-suppressor 
cells (CD8 
positive), 
monocytes 
(CD14 positive), 
B cells (CD20 
positive), 
endothelial cells 
(CD62e 
positive), 
erythrocytes 
(glyco-A 
positive) and 
granulocytes 
(CD66b 
positive), 
annexin V and 
TF positive MPs 
 Simvastatin (193)(194) PMPs GPIX 
positive, 
Monocyte 
derived MPs 
CD14/ Annexin 
V positive, EMPs 
CD51/ Annexin 
V positive 
Hyperlipidemia, 
HTN 
 Atorvastatin(197) PMPs, surface 
markers CD42a 
(Glycoprotein 
IX), together 
with either CD61 
(GPIIIa), CD62P 
(P-selectin) or 
CD142 (TF) 
Hyperlipidemia 
 Bezafibrate(198) PMPs CD42b 
positive 
Hyperlipidemia 
 Probucol(185) PMPs GPIX 
positive , 
Monocyte 
derived MPs 
CD14 positive 
Hyperlipidemia 
 Eicosapentaenoic 
acid(196)(199)(200) 
PMPs CD42b 
and CD42a 
(glycoprotein Ib 
and IX) positive 
Hyperlipidemia 
 Vitamin C(201) EMPs CD31 
positive, PMPs 
GPIb positive 
Acute myocardial 
infarction 
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Antidiabetic Acarbose(202) PMPs CD42b 
and CD42a 
(glycoprotein Ib 
and IX) positive 
 
 Miglitol(203) PMPs CD42b 
and CD42a 
(glycoprotein Ib 
and IX) positive 
 
 Pioglitazone(204) EMPs CD31 
positive 
 
Abbreviations: CD cluster of differentiation, HTN Hypertension, EMP endothelial derived 
MP, PMP platelet derived MP , GP glycoprotein, TF Tissue factor, DM diabetes mellitus 
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Table 8. Studies with Microparticles (MPs) in Acute Coronary Syndrome populations (ACS) 
Type of MPs Conclusion Reference 
Surface markers: Anexin V, 
anti-CD3, anti-CD11a, anti-
CD31, anti-CD146, and anti-
GP Ib 
Higher levels of procoagulant 
EMPs in Patients with ACS 
compare with patients with no 
CAD or SA 
Mallat Z et al(259) 
Combination of CD31 
(PECAM-1) or CD51 (aV�3, 
vitronectin receptor) with 
CD42. EMPs and PMPs 
(PMPs CD42 positive) 
EMPs were elevated in 
patients with CAD compared 
with control subjects, 
CD31�EMPs higher in 
patients with ACS compare 
with SA,  among patients with 
a first MI, CD31 EMPs 
released in ACS and CD51 
released in SA. 
Bernal-Mizrachi L et 
al(260) 
Leukocyte derived MP 
CD11a positive , EMPs 
CD31 positive, PMPs GPIb 
positive, Anexin V positive 
Early decrease of procoagulant 
MPs in patients with STEMI 
treated with PPCI and 
abciximab compare with 
patients treated only with 
PPCI. 
Morel O et al(261) 
EMPs CD146 and CD 106 
(VCAM-1) positive 
High density of VCAM-1 
expressed on EMPs from 
patients with ACS 
Radecke CE et al(262) 
Annexin V-binding MPs, 
MPs CD42b positive, EMPs 
CD144 positive and 
monocyte derived MPs CD14 
positive 
In NSTEMI, EMP and 
monocyte derived MPs were 
independently predictive for 
future admissions related to 
heart failure  and PMPs for 
major bleedings 
Montoro-García S et 
al(263) 
EMPs CD144 positive, PMPs 
CD41 positive and leukocyte-
derived MPs CD45 positive 
Variation of levels of different 
origin MPs associated with 
time in patients before and 
Zhou B et al(264) 
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after PPCI 
Surface markers : anti- 
CD11a (leukocytes), anti-
CD31 (endothelial cells), 
anti-CD42b (endothelial 
cells), and anti-CD146 
(platelets), Anexin V for 
apoptotic MPs 
Increased levels of MPs in 
culprit coronary arteries after 
STEMI and significant 
reduction after successful PCI 
Min P-K et al(266) 
Lymphocyte derived MPs 
CD45/CD3 positive, 
monocyte derived MPs CD14 
positive, EMPs CD146 
positive or CD62e positive,  
granulocytes derived MPs 
CD66b positive, other surface 
markers: CD142 (TF), 
Anexin V, CD31 
Increased levels of MPs in 
culprit coronary arteries after 
STEMI, levels of MPs 
positively correlated to time of 
revascularisation post STEMI 
Suades R et al(267) 
EMPs CD31 positive/CD42 
negative, PMPs CD31 
positive/CD42 positive, 
anexin V positive 
ACS are associated with 
higher levels of circulating 
MPs compare with SA 
patients. In SA the degree of 
atherosclerotic plaque is not 
related with the levels of 
plasma MPs 
Biasucci LM et al(268) 
TF positive MPs Thrombolysis failure in acute 
MI is associated with higher 
levels of procoagulant MPs 
Huisse M-G et al(265) 
TF positive MPs MPs were lower as the severity 
of the stable angina/ACS was 
increasing (stable CAD vs UA 
vs MI) 
Maly M et al(270) 
PMPs CD42 positive, 
Leukocyte derived MPs 
Increased levels of MPs in 
ACS and positive correlation 
Stępień E et al.(64) 
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CD45 positive , Monocyte 
derived MPs CD14 positive, 
EMPs CD31, CD51/61, 
CD34  positive and activated 
tissue factor positive (TF) 
MPs  
of MP levels with platelet 
activation markers 
EMPs CD31 positive/ 
CD42negative  and CD144 
positive, PMPs CD31/CD42 
positive 
EMPs and PMPs reflect the 
size of myocardium at risk in 
patients with STEMI 
Jung C et al(269) 
Abbreviations: CD Cluster of differentiation, EMP endothelial MP, STEMI ST elevation 
myocardial infarction, PPCI primary percutaneous coronary intervention , TF tissue factor, 
PMP platelet derived MP, CAD coronary artery disease, NSTEMI non- ST elevation 
myocardial infarction, SA stable angina, VCAM-1 Vascular cell adhesion protein 1, 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
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Table 9. Studies with Microparticles (MPs) in Heart Failure 
Type of MPs Conclusion Reference 
Annexin V-binding MPs, MPs 
CD42b positive, EMPs CD144 
positive and monocyte derived 
MPs CD14 positive 
In NSTEMI, EMP and 
monocyte derived MPs were 
independently predictive for 
future admissions related to 
heart failure 
Montoro-García S et 
al(263) 
Annexin V-binding MPs, MPs 
CD42b positive, EMPs CD144 
positive 
Annexin V-MPs levels 
appear to reflect accurately 
the acute decompensated 
phase in systolic heart failure 
Montoro-García S et 
al(281) 
CD 31/Annexin V positive EMPs was increased in 
patients with LV dysfunction 
compared with those with 
normal or preserved LV 
function. 
Bulut D et al(279) 
Surface markers for EMPs: 
CD31 (platelet endothelial cell 
adhesion molecule [PECAM]-1), 
CD144 (vascular endothelial 
[VE]-cadherin), CD62E (E-
selectin) and annexin V 
EMPs levels are higher in 
patients with HFrEF and 
increased Body Mass Index 
(BMI>25kg/m2) compare 
with other patients with lower 
BMI. 
Berezin AE et al(280) 
Surface markers for EMPs: 
CD31, CD62E, CD105, Annexin 
V 
Adding CD31/annexin V 
positive EMPs to CD14/ 
CD309 positive cell ratio to 
other variables predict the 
risk of HFpEF. 
Berezin AE et al(62) 
EMPs CD31/CD62E positive EMPs in post-transplant 
patients are consistent with 
increased apoptotic activity 
Garcia S et al(282) 
Red blood cell derived MPs 
(CD235 positive), leukocyte 
MPs (CD45 positive), platelet 
(CD31/CD41positive) and EMPs 
(CD31 positive/CD41 negative, 
CD62e positive, CD144 
positive) 
All types of MPs were 
elevated in patients with 
LVAD compare with patients 
with CAD and healthy 
subjects due to haemolysis 
and disturbed endothelial 
integrity 
Sansone R et al(68) 
EMPs LVAD do not cause vascular 
damage 3 months after 
implantation. 
Ivak P et al(283) 
Surface markers for EMPs: 
CD31, CD41a, CD64, CD105, 
CD144, CD62E and Annexin V. 
PMPs  CD41a positive 
Patients with HF and 
metabolic syndrome have 
higher levels of 
CD31/Annexin V positive 
EMPs in addition with lower 
levels of CD62E positive 
EMPs compare with healthy 
subjects. 
Berezin AE et al(66) 
Surface markers: CD31, CD144, 
CD62E, CD14, CD45, Annexin 
Patients with PPCM appears 
to have elevated levels of  
Walenta K et al(284) 
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V, CD62P, CD42b activated EMPs (CD144 
positive) and PMPs (CD42b 
positive) compare with 
patients with ischaemic 
cardiomyopathy 
Abbreviations: CD cluster of differentiation, EMP Endothelial derived MP, NSTEMI non ST 
elevation myocardial infarction, PMP platelet derived MP, HFrEF heart failure with reduced 
enjection fraction, HFpEF heart failure with preserved enjection fraction, LV left ventricle, 
LVAD LV assisting device, CAD coronary artery disease, BMI body mass index, PPCM post 
partum cardiomyopathy.  
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Table 10. Studies where Microparticle levels are associated with outcomes 
Type of MPs Prognostic value Reference 
Annexin V-binding MPs, 
MPs CD42b positive, EMPs 
CD144 positive and 
monocyte derived MPs CD14 
positive 
In NSTEMI, EMP and 
monocyte derived MPs were 
independently predictive for 
future admissions related to 
heart failure 
Montoro-García S et al(263) 
EMPs apoptotic 
CD31/Annexin V positive 
CD31/Annexin V positive 
MPs is an independent 
predictor of MACCE in 
stable CAD patients 
Sinning J-M et al(295) 
Monocyte-derived MPs 
(Surface markers: CD14+, 
CD14/CD11b and 
CD14/CD142) 
Monocyte-derived MPs 
levels assessed in the acute 
phase of STEMI are related 
to the prognosis of long term 
CV death  
Chiva-Blanch G et al(296) 
Annexin V positive, CD41 
positive PMPs,  CD235a 
positive erythrocyte derive 
MPs 
CD235a positive erythrocyte 
derive MPs concentrations 
appear to be positively 
associated with MACCE in 
patients with STEMI and 
PPCI 
Giannopoulos G et al(297) 
Surface markers: Annexin V, 
TF , CD41, CD66b 
In the plasma of patients with 
ACS, the TF activity is a 
consequence of circulating 
MPs and is an independent 
predictor for MACCE  
Steppich BA et al(298) 
EMPs CD146, CD31 Higher EMP levels had a 
higher risk of MACCE in 
ACS patients. 
Fan Y et al(299) 
EMPs CD31/Annexin V 
positive 
EMPs levels were associated 
with increased mortality and 
recurrent hospitalization due 
to CHF 
Berezin AE et al(300) 
Apoptotic MPs Annexin V 
positive 
elevation of apoptotic MP 
levels in LVAD-supported 
patients are associated with 
increased risk for adverse 
events. 
Nascimbene A et al(301) 
EMPs CD62e positive, 
CD144 positive, CD31 
positive (+)/CD41 negative 
leukocytes-derived MPs 
CD45 positive 
Elevated levels of CD62e 
positive EMPs in PHTN 
patients prior to treatment are 
associated with adverse 
clinical events 
Amabile N et al(302) 
Abbreviations: MACCE Major adverse cardiovascular and cerebral event , CD cluster of 
differentiation, EMP endothelial derived MP, NSTEMI non-ST elevation myocardial 
infarction, CAD coronary artery disease, STEMI ST elevation myocardial infarction, CV 
cardiovascular, TF tissue factor, ACS acute coronary syndrome, LVAD Left ventricular 
assisting device, PHTN pulmonary hypertension 
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